These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34032171)

  • 41. Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community.
    Iqbal L; Terlau TJ; Hernandez A; Woods K
    Cureus; 2021 Jul; 13(7):e16477. PubMed ID: 34430093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report.
    Sam KS; Khosla P; Taneja V; Dessai R
    Commun Med (Lond); 2024 Jun; 4(1):103. PubMed ID: 38824216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States.
    Bailey LC; Razzaghi H; Burrows EK; Bunnell HT; Camacho PEF; Christakis DA; Eckrich D; Kitzmiller M; Lin SM; Magnusen BC; Newland J; Pajor NM; Ranade D; Rao S; Sofela O; Zahner J; Bruno C; Forrest CB
    JAMA Pediatr; 2021 Feb; 175(2):176-184. PubMed ID: 33226415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access.
    Kwan BM; Sobczak C; Beaty L; Wynia MK; DeCamp M; Owen V; Ginde AA
    J Gen Intern Med; 2022 Oct; 37(13):3426-3434. PubMed ID: 35790666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health Center Testing for SARS-CoV-2 During the COVID-19 Pandemic - United States, June 5-October 2, 2020.
    Romero L; Pao LZ; Clark H; Riley C; Merali S; Park M; Eggers C; Campbell S; Bui C; Bolton J; Le X; Fanfair RN; Rose M; Hinckley A; Siza C
    MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1895-1901. PubMed ID: 33332299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan.
    Osugi Y; Iwata H; Imai Y; Kobayashi D; Hirashima R
    Cureus; 2022 Feb; 14(2):e21882. PubMed ID: 35273850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score.
    Johnson PW; Kunze KL; Senefeld JW; Sinclair JE; Isha S; Satashia PH; Bhakta S; Cowart JB; Bosch W; O'Horo J; Shah SZ; Wadei HM; Edwards MA; Pollock BD; Edwards AJ; Scheitel-Tulledge S; Clune CG; Hanson SN; Arndt R; Heyliger A; Kudrna C; Bierle DM; Buckmeier JR; Seville MTA; Orenstein R; Libertin C; Ganesh R; Franco PM; Razonable RR; Carter RE; Sanghavi DK; Speicher LL
    Mayo Clin Proc Innov Qual Outcomes; 2023 Apr; 7(2):109-121. PubMed ID: 36644593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents.
    Murillo M; Lomiguen C; Terrell M; King A; Lin J; Ferretti S
    Aging Dis; 2022 Oct; 13(5):1523-1531. PubMed ID: 36186125
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Nov; 21(11):1359-1362. PubMed ID: 34555986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Universal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Testing Uptake in the Labor and Delivery Unit: Implications for Health Equity.
    Kernberg A; Kelly J; Nazeer S; Russell S; Tuuli M; Stout MJ; Raghuraman N; Carter EB
    Obstet Gynecol; 2020 Dec; 136(6):1103-1108. PubMed ID: 32858567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.
    Sloan B; Duhaime E; Sandkovsky U; Berhe M
    Proc (Bayl Univ Med Cent); 2022; 35(3):339-341. PubMed ID: 35518791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan.
    Komagamine J; Yabuki T; Yoshihara S; Tanaka N
    J Gen Fam Med; 2022 May; 23(3):158-163. PubMed ID: 35509339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19 Monoclonal Antibody Administration Linked to Drop in Blood Pressure: A Retrospective Cohort Study.
    CarlLee S; Diaz-Cruz A; Brand R; Reece S; Robinson S; West J; Dare RK; Jensen H
    Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):65-67. PubMed ID: 36787476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
    Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
    Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Impact of Casirivimab-Imdevimab Antibody Cocktail in Patients Amidst and Post COVID 19 Treatment: A Retro-Prospective Comparative Study in India.
    Joy AP; Karattuthodi MS; Chandrasekher D; Augustine AT
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic and features of SARS-CoV-2 infection in Gabon.
    Mveang Nzoghe A; Padzys GS; Maloupazoa Siawaya AC; Kandet Yattara M; Leboueny M; Avome Houechenou RM; Bongho EC; Mba-Mezeme C; Mvoundza Ndjindji O; Biteghe-Bi-Essone JC; Boulende A; Essone PN; Ndong Sima CAA; Minkobame U; Zang Eyi C; Ndeboko B; Voloc A; Meye JF; Ategbo S; Djoba Siawaya JF
    Sci Rep; 2021 May; 11(1):9672. PubMed ID: 33958601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis.
    Kakinoki Y; Yamada K; Tanino Y; Suzuki K; Ichikawa T; Suzuki N; Asari G; Nakamura A; Kukita S; Uehara A; Saito S; Kuroda S; Sakagami H; Nagashima Y; Takahashi K; Suzuki S
    Int J Infect Dis; 2022 Apr; 117():189-194. PubMed ID: 35176486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of Monoclonal Antibody Therapy for Preventing COVID-19 Hospitalization and Mortality in a Statewide Population.
    Chambers LC; Chu HT; Lewis N; Kamat G; Fortnam T; Chan PA; Lasher L; Hogan JW
    R I Med J (2013); 2023 Jun; 106(5):42-48. PubMed ID: 37195162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy.
    Folkman R; Blennow O; Tovatt T; Pettersson K; Nowak P
    Infection; 2023 Feb; 51(1):261-263. PubMed ID: 35482208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.